Ultragenyx Pharmaceutical Inc (RARE) CFO & Executive Vice President Shalini Sharp Sold $2.1 million of Shares (Guru Focus)
CFO & Executive Vice President of Ultragenyx Pharmaceutical Inc., Shalini Sharp, sold 29,113 shares of RARE on 05/19/2020 at an average price of $73.33 a share. The total sale was $2.1 million. Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
Thursday 5/21 Insider Buying Report: AXLA, FRG (Nasdaq.com)
On Monday, Axcella Health’s Director, David R. Epstein, made a $237,500 purchase of AXLA, buying 50,000 shares at a cost of $4.75 each. Axcella Health is trading up about 20.9% on the day Thursday. Before this latest buy, Epstein purchased AXLA at 7 other times during the past year, for a total investment of $396,973 at an average of $6.49 per share. And at Franchise Group, there was insider buying on Monday, by Director Patrick A. Cozza who bought 10,000 shares for a cost of $14.05 each, for a total investment of $140,500. This purchase marks the first one filed by Cozza in the past twelve months. Franchise Group is trading up about 8.3% on the day Thursday. So far Cozza is in the green, up about 12.5% on their buy based on today’s trading high of $15.80.
The President of II-VI (NASDAQ: IIVI) is Selling Shares (Analyst Ratings)
Yesterday, the President of II-VI (IIVI), BASHAW WALTER ROBERT II, sold shares of IIVI for $502.5K. In addition to BASHAW WALTER ROBERT II, one other IIVI executive reported Sell trades in the last month. Based on II-VI’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $627 million and quarterly net profit of $5.92 million. In comparison, last year the company earned revenue of $342 million and had a net profit of $24.64 million. The company has a one-year high of $48.68 and a one-year low of $19.00.
CMA Fights Stockbroker in Row Over KenolKobil Insider Trading (BusinessDailyAfrica.com)
The Capital Markets Authority (CMA) wants an appeal filed by former head of one of Kenya’s biggest stockbrokers to overturn his punishment over the KenolKobil insider trading case dismissed. The regulator wants the appeal by Andre DeSimone, who left his position as chief executive of Kestrel Capital in April last year after the insider trading allegations, to be declared time barred. The regulator says that the law requires that a demand for an appeal be done within 15 days, arguing that Mr DeSimone is fighting the punishment more than nine months after it was meted out.
JPMorgan Warns on Insider Trading Risk in Fast-Moving CLO Market (NewsMax.com)
JPMorgan Chase & Co. is warning clients tempted to bet on bonds backed by loans to business and consumers that they may face trading counterparties benefitting from insider knowledge. The bank’s securitized products sales team told clients in an email last month seen by Bloomberg News it has received increased interest from originators and sponsors of securitizations, as well as managers of collateralized loan obligations, in buying securities from their own deals.
